Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 6. Summary of Tumor Response in Studies of First-line Treatment With EGFR-TK Inhibitors (Single Agent) for Advanced NSCLC

Study ID Diagnosis
(no. of patients)
[agent]
Sub-groups N Survival from start
of treatment
Tumor response
Median
(months)
1-year (%) % CR % PR % SD % DP % NE
All NSCLC
Niho, et al., 200411 NSCLC
(37)
[Gefitinib]
- - 37 - - - - 0 27 - - - - - -
Giaccone, et al., 200512 NSCLC
(53)
[Erlotinib]
- - 53 - - - - 2 23 30 32 13
Kasahara, et al., 200513 NSCLC
(30)
[Gefitinib]
- - 30 10 43.3 0 33 30 37 - -
Suzuki, et al., 200514 NSCLC
(34)
[Gefitinib]
- - 34 - - - - 0 26 - - - - - -
Reck, et al., 200515 NSCLC
(58)
[Gefitinib]
- - 58 - - - - 2 3 40 48 - -
D'Addario, et al., 200516 NSCLC
(63)
[Gefitinib]
- - 63 10 - - 2 8 27 57 6
Lee, et al., 200517 NSCLC
(55)
[Gefitinib]
- - 55 Not
reached
76.1 4 57 11 28 - -
BAC
West, et al., 200418 NSCLC
(138)
[Gefitinib]
Chemo-naive
Previous treatment
(26%)
67
21
12
10
~50
~50
6
0
15
10
- - - - - -
Kris, et al., 200419 NSCLC
(69)
[Erlotinib]
- - 59 Median not
reached
58 - - 25
(15-38)
- - - - - -
Elderly
Jackman, et al., 200521 NSCLC
(58)
[Erlotinib]
- - 66 11 - - 0 12 48 39 - -
Poor PS
Dickson, et al., 200422 NSCLC
(25)
[Gefitinib]
- - 18 Median not
reached
Follow up
< 1 year
- - - - 61 39 - -

Abbreviations: BAC = bronchoalveolar carcinoma; CR = complete response; DP = disease progression; EGFR-TK = epidermal growth factor receptor tyrosine kinase; NE = not evaluable; NSCLC = non-small cell lung cancer; no. = number; PR = partial response; SD = stable disease.

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care